Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28198434 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL28198474 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL4584664 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL4584005 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL4584723 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL4585309 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL3309122 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL10577019 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL4584899 | 1.00 | PLA2G4A (0.43) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 | |
| SCHEMBL244221 | 0.98 | PLA2G4A (0.41) | PLA2G4AALDH1A1KCNH2TLR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334391-B2 | Functionalized heteroacenes | XEROX CORPORATION (US) | 2012-12-18 | — | — | US | claimed |
| US-7372071-B2 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | claimed |
| US-20070260069-A1 | Functionalized heteroacenes | XEROX CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070235721-A1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORPORATION | 2007-10-11 | — | — | US | claimed |
| EP-1843410-B1 | Functionalized heteroacenes and electronic devices generated therefrom | XEROX CORP (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1843410-A2 | Functionalized heteroacenes and electronic devices generated therefrom | Xerox Corporation (US) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260069-A1 | Functionalized heteroacenes | SOD1, AHR, NR0B2 | PLA2G4A 4340/4885ALDH1A1 2135/4885KCNH2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.